Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Abnormality of the Central Canal of the Spinal Cord in Syringomyelia in a Patient With a Basal Skull Malformation (SYRCANAL)

17. Juli 2026 aktualisiert von: University Hospital, Bordeaux

The aim of this study is to analyze the association between a deformity of the cranial portion of the central spinal canal and syringomyelia in patients with a Chiari-type malformation of the craniocervical junction.

The investigators hypothesize that Chiari malformation, defined by the herniation of the cerebellar tonsils through the foramen magnum, may be responsible for a deformation of the cranial portion of the central spinal canal, and that this deformation is associated with the presence of syringomyelia in patients with this malformation.

Studienübersicht

Status

Noch keine Rekrutierung

Intervention / Behandlung

Detaillierte Beschreibung

Chiari Malformation Type I (CM-I) is a congenital anomaly characterized by downward displacement of the cerebellar tonsils through the foramen magnum, which may disrupt cerebrospinal fluid (CSF) circulation at the craniovertebral junction. The condition generally results from underdevelopment of the posterior cranial fossa, leading to insufficient space for the cerebellum. This anatomical abnormality can cause a wide range of heterogeneous symptoms, including occipital headaches triggered by coughing or exertion, neck pain, dizziness, balance disturbances, paresthesia, limb weakness, and swallowing difficulties.

One of the most concerning complications is syringomyelia/hydromyelia, which corresponds to the development of fluid-filled cavities within the spinal cord. These cavities may either be adjacent to the central canal (syringomyelia) or result from dilation of the central canal itself (hydromyelia). Associated spinal cord involvement may lead to specific neurological symptoms and is often a major indication for surgical treatment of Chiari malformation.

The decision to perform surgical decompression of the craniovertebral junction must balance the potential benefits against the associated risks. Furthermore, surgical outcomes remain variable and sometimes uncertain. Some symptoms may persist despite surgery, and syringomyelia regression is inconsistent. A better understanding of the pathophysiology of syringomyelia associated with Chiari malformation is therefore essential to improve patient selection and optimize surgical strategies.

Although the pathophysiology of syringomyelia in Chiari malformation has been investigated in several studies, it remains only partially understood. Recently, the position of the obex has been suggested to be associated with the presence of syringomyelia in patients with Chiari malformation. The obex is the neurological structure located at the cranial end of the central canal. Based on previous findings, investigators hypothesize that a low-lying obex may induce deformation of the central canal, creating a folding or kinking effect that could explain downstream canal dilation. Our primary hypothesis is therefore that the morphology of the central canal at the cervicomedullary junction (including angulation, folding, or compression) is a key factor influencing the presence or absence of associated hydromyelia/syringomyelia and, consequently, clinical severity.

Animal studies support a pathophysiological cascade involving initial mechanical deformation of the central canal followed by pericanal inflammation contributing to syringomyelia formation. According to this novel hypothesis, cerebellar tonsillar descent without associated central canal deformation would confer a lower risk of syringomyelia and unfavorable clinical progression than cases involving deformation of the cranial portion of the central canal.

In vivo visualization and morphological assessment of the cranial portion of the ependymal central canal using MRI therefore offer the potential to identify new risk markers for Chiari malformation that may ultimately assist surgical decision-making. However, when the canal is not dilated, visualization remains challenging, as does the identification of potential pericanal inflammation.

Several years ago, Tourdias et al. developed a specific MRI sequence known as White Matter-nulled (WMn) MPRAGE, which enhances contrast between structures of the central nervous system, including the thalamus, thereby improving the accuracy of thalamic assessment in pathological conditions. More recently, this group demonstrated that the WMn-MPRAGE sequence can be adapted for spinal cord imaging, maximizing the detection of spinal cord lesions. In collaboration with the Anatomy Laboratory of the University of Bordeaux, it was demonstrated that WMn-MPRAGE enables reliable visualization of the spinal cord central canal in healthy subjects when compared with previous anatomical specimen studies. Furthermore, recent advances in spinal cord diffusion MRI, particularly through artificial intelligence-based denoising methods, now enable detailed assessment of spinal cord microstructure and may allow quantification of biomarkers associated with pericanal inflammation.

Thus, the pathophysiology of Chiari Malformation Type I remains incompletely understood. Investigators hypothesize that analysis of the morphology of the cranial portion of the ependymal central canal using WMn-MPRAGE imaging, combined with assessment of the adjacent spinal cord microstructure, may provide novel biomarkers of associated syringomyelia risk and clinical severity.

Studientyp

Interventionell

Einschreibung (Geschätzt)

50

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studieren Sie die Kontaktsicherung

Studienorte

      • Bordeaux, Frankreich
        • Bordeaux University Hospital
        • Kontakt:
        • Hauptermittler:
          • Jean-Rodolphe VIGNES, Pr
        • Unterermittler:
          • Paul ROBLOT, Dr

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Erwachsene
  • Älterer Erwachsener

Akzeptiert gesunde Freiwillige

Nein

Beschreibung

Inclusion Criteria:

  • Adult patients being treated for Chiari malformation or syringomyelia at Bordeaux University Hospital
  • Patients admitted for an initial surgical consultation regarding Chiari malformation with or without syringomyelia at Bordeaux University Hospital
  • Individuals enrolled in or covered by a social security program.
  • Free, informed, and express consent (confirmed in writing) (no later than the day of enrollment and prior to any examination required by the study).

Exclusion Criteria:

  • Pregnant or breastfeeding patients
  • Contraindications to MRI
  • Individuals deprived of their liberty by judicial or administrative order,
  • Adults subject to legal protective measures (guardianship, conservatorship, judicial protection).
  • Patients who have previously undergone surgery for a Chiari malformation or a posterior fossa malformation

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Grundlegende Wissenschaft
  • Zuteilung: Nicht randomisiert
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Patients with Chiari malformation with associated syringomyelia
Magnetic Resonance Imaging (MRI) using T1, T2, White-Matter nulled (WMn), and diffusion sequences
Experimental: Patients with Chiari malformation without associated syringomyelia
Magnetic Resonance Imaging (MRI) using T1, T2, White-Matter nulled (WMn), and diffusion sequences

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Deformation of the central canal of the spinal cord
Zeitfenster: At inclusion (D0)
The central canal deformation index of the spinal cord, calculated based on the angle of the curves and the length of each segment between two curves.
At inclusion (D0)

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Protrusion of the cerebellar tonsils
Zeitfenster: at inclusion (day 0)

Protrusion of the cerebellar tonsils into the foramen magnum on T2-weighted MRI.

Commonly accepted definition of Chiari malformation Type I: cerebellar tonsils extending more than 5 mm below the McRae line on MRI. The McRae line is defined as the anatomical line connecting the basion and the opisthion, corresponding to the anterior and posterior margins of the foramen magnum.

at inclusion (day 0)
Presence and dimensions of syringomyelia
Zeitfenster: At inclusion (day 0)
The presence and dimensions of syringomyelia on MRI using T2 and WMn-MPRAGE sequences
At inclusion (day 0)
Distance between the obex and the foramen magnum
Zeitfenster: At inclusion (Day 0)
Distance between the obex and the foramen magnum on T2-weighted and WMn-MPRAGE MRI sequences
At inclusion (Day 0)
Diffusion MRI parameter (1)
Zeitfenster: At inclusion (Day 0)
Diffusion MRI parameter (mean diffusivity) in the pericanalicular region
At inclusion (Day 0)
Diffusion MRI parameter (2)
Zeitfenster: At inclusion (Day 0)
Diffusion MRI (anisotropy fraction) in the pericanalicular region
At inclusion (Day 0)

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

30. September 2026

Primärer Abschluss (Geschätzt)

30. September 2029

Studienabschluss (Geschätzt)

30. September 2029

Studienanmeldedaten

Zuerst eingereicht

8. Juni 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

17. Juli 2026

Zuerst gepostet (Tatsächlich)

22. Juli 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

22. Juli 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

17. Juli 2026

Zuletzt verifiziert

1. Juli 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur MRI

Abonnieren